Panel Discussion: Maximize the Value of Classical Payloads Through Smarter Design & Better Development Decisions
- Assess whether the performance ceiling of established payloads is driven by the payload itself or by broader ADC design factors, including antibody biology, internalization dynamics, and target selection
- Explore the impact of tumor biology and cell-cycle kinetics on ADC efficacy, discussing whether reliance on traditional cytotoxic mechanisms leaves significant tumor populations untreated and how developers can address these limitations
- Examine how linker design, payload permeability, and medicinal chemistry have been used to fine-tune bystander killing, highlighting lessons from both efficacy gains and toxicity liabilities
- Debate how antibody engineering, immune-mediated mechanisms of action, and novel ADC platforms can unlock greater value from proven payload classes without requiring entirely new warheads